Suppr超能文献

半乳糖凝集素 3 与 CD47 协同作用抑制胃癌腹膜转移中的吞噬作用和 T 细胞免疫。

Galectin-3 Cooperates with CD47 to Suppress Phagocytosis and T-cell Immunity in Gastric Cancer Peritoneal Metastases.

机构信息

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Department of Molecular and cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

出版信息

Cancer Res. 2023 Nov 15;83(22):3726-3738. doi: 10.1158/0008-5472.CAN-23-0783.

Abstract

UNLABELLED

The peritoneal cavity is a common site of gastric adenocarcinoma (GAC) metastasis. Peritoneal carcinomatosis (PC) is resistant to current therapies and confers poor prognosis, highlighting the need to identify new therapeutic targets. CD47 conveys a "don't eat me" signal to myeloid cells upon binding its receptor signal regulatory protein alpha (SIRPα), which helps tumor cells circumvent macrophage phagocytosis and evade innate immune responses. Previous studies demonstrated that the blockade of CD47 alone results in limited clinical benefits, suggesting that other target(s) might need to be inhibited simultaneously with CD47 to elicit a strong antitumor response. Here, we found that CD47 was highly expressed on malignant PC cells, and elevated CD47 was associated with poor prognosis. Galectin-3 (Gal3) expression correlated with CD47 expression, and coexpression of Gal3 and CD47 was significantly associated with diffuse type, poor differentiation, and tumor relapse. Depletion of Gal3 reduced expression of CD47 through inhibition of c-Myc binding to the CD47 promoter. Furthermore, injection of Gal3-deficient tumor cells into either wild-type and Lgals3-/- mice led to a reduction in M2 macrophages and increased T-cell responses compared with Gal3 wild-type tumor cells, indicating that tumor cell-derived Gal3 plays a more important role in GAC progression and phagocytosis than host-derived Gal3. Dual blockade of Gal3 and CD47 collaboratively suppressed tumor growth, increased phagocytosis, repolarized macrophages, and boosted T-cell immune responses. These data uncovered that Gal3 functions together with CD47 to suppress phagocytosis and orchestrate immunosuppression in GAC with PC, which supports exploring a novel combination therapy targeting Gal3 and CD47.

SIGNIFICANCE

Dual inhibition of CD47 and Gal3 enhances tumor cell phagocytosis and reprograms macrophages to overcome the immunosuppressive microenvironment and suppress tumor growth in peritoneal metastasis of gastric adenocarcinoma.

摘要

未注明

胃腺癌(GAC)转移的常见部位是腹腔。腹膜癌病(PC)对目前的治疗方法有抵抗力,并导致预后不良,这凸显了需要确定新的治疗靶点。CD47 与信号调节蛋白α(SIRPα)结合后,向髓样细胞发出“不要吃我”的信号,这有助于肿瘤细胞逃避巨噬细胞吞噬作用并逃避先天免疫反应。先前的研究表明,单独阻断 CD47 仅导致有限的临床益处,这表明需要同时抑制其他靶标(S)与 CD47 一起发挥强大的抗肿瘤反应。在这里,我们发现 CD47 在恶性 PC 细胞上高度表达,并且 CD47 的升高与预后不良相关。半乳糖凝集素-3(Gal3)的表达与 CD47 的表达相关,Gal3 和 CD47 的共表达与弥漫型、低分化和肿瘤复发显著相关。Gal3 的耗竭通过抑制 c-Myc 与 CD47 启动子结合来降低 CD47 的表达。此外,与 Gal3 野生型肿瘤细胞相比,将 Gal3 缺陷型肿瘤细胞注入野生型和 Lgals3-/-小鼠中,导致 M2 巨噬细胞减少和 T 细胞反应增加,这表明肿瘤细胞衍生的 Gal3 在 GAC 进展和吞噬作用中比宿主衍生的 Gal3 发挥更重要的作用。Gal3 和 CD47 的双重阻断协同抑制肿瘤生长,增加吞噬作用,重塑巨噬细胞,并增强 T 细胞免疫反应。这些数据揭示了 Gal3 与 CD47 一起发挥作用,以抑制吞噬作用并在伴有 PC 的 GAC 中协调免疫抑制,这支持探索针对 Gal3 和 CD47 的新型联合治疗方法。

意义

CD47 和 Gal3 的双重抑制增强了肿瘤细胞的吞噬作用,并重塑了巨噬细胞,以克服免疫抑制微环境,抑制胃腺癌腹膜转移中的肿瘤生长。

相似文献

1
4
CD47/SIRPα axis: bridging innate and adaptive immunity.
J Immunother Cancer. 2022 Jul;10(7). doi: 10.1136/jitc-2022-004589.
5
Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody.
Cancer Immunol Immunother. 2022 Feb;71(2):473-489. doi: 10.1007/s00262-021-03010-6. Epub 2021 Jul 10.
6
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7. doi: 10.1073/pnas.1121623109. Epub 2012 Mar 26.
7
Extracellular Matrix Protein Tenascin C Increases Phagocytosis Mediated by CD47 Loss of Function in Glioblastoma.
Cancer Res. 2019 May 15;79(10):2697-2708. doi: 10.1158/0008-5472.CAN-18-3125. Epub 2019 Mar 21.
10
The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.
Life Sci. 2021 May 15;273:119150. doi: 10.1016/j.lfs.2021.119150. Epub 2021 Mar 1.

引用本文的文献

1
mutations promote an immunosuppressive tumor microenvironment via to confer immune evasion in head and neck cancer.
Cancer Drug Resist. 2025 Aug 22;8:42. doi: 10.20517/cdr.2025.124. eCollection 2025.
2
Beyond the Limit: MYC Mediates Tumor Immune Escape.
Pharmaceuticals (Basel). 2025 Jun 29;18(7):978. doi: 10.3390/ph18070978.
4
Galectins as Master Regulators of Gastric Cancer Progression.
Cells. 2025 Jul 16;14(14):1090. doi: 10.3390/cells14141090.
7
Novel immunotherapy for gastric cancer: targeting the CD47-SIRPα axis.
Cancer Metastasis Rev. 2025 May 29;44(2):52. doi: 10.1007/s10555-025-10269-z.
9
Lgals3 Promotes Calcium Oxalate Crystal Formation and Kidney Injury Through Histone Lactylation-Mediated FGFR4 Activation.
Adv Sci (Weinh). 2025 Mar;12(12):e2413937. doi: 10.1002/advs.202413937. Epub 2025 Feb 4.
10
Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy.
Hum Vaccin Immunother. 2025 Dec;21(1):2459458. doi: 10.1080/21645515.2025.2459458. Epub 2025 Jan 28.

本文引用的文献

1
Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities.
Nat Cancer. 2021 Sep;2(9):962-977. doi: 10.1038/s43018-021-00240-6. Epub 2021 Aug 16.
2
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication.
Nat Med. 2022 Feb;28(2):333-344. doi: 10.1038/s41591-021-01625-x. Epub 2022 Jan 13.
3
Targeting CD47 for cancer immunotherapy.
J Hematol Oncol. 2021 Oct 30;14(1):180. doi: 10.1186/s13045-021-01197-w.
5
Immunotherapy in Acute Myeloid Leukemia: Where We Stand.
Front Oncol. 2021 May 10;11:656218. doi: 10.3389/fonc.2021.656218. eCollection 2021.
6
Current treatment and recent progress in gastric cancer.
CA Cancer J Clin. 2021 May;71(3):264-279. doi: 10.3322/caac.21657. Epub 2021 Feb 16.
8
The CD47-SIRPα Immune Checkpoint.
Immunity. 2020 May 19;52(5):742-752. doi: 10.1016/j.immuni.2020.04.011.
9
Phagocytosis checkpoints as new targets for cancer immunotherapy.
Nat Rev Cancer. 2019 Oct;19(10):568-586. doi: 10.1038/s41568-019-0183-z. Epub 2019 Aug 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验